FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1200 October 19, 2000 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

Edited by Ronald M. Bukowski and Andrew C. Novick. 434 pp., illustrated. Totowa, N.J., Humana Press, 2000. $145. ISBN 0-89603-781-9.

Renal-cell carcinoma is sometimes said to be the cancer that is most resistant to both chemotherapy and radiation therapy. Once renal-cell carcinoma has spread beyond the kidney, therapeutic options are limited. In the United States alone, 12,000 people die each year of metastatic renal cancer. As the authors of the chapter on chemotherapy in this book emphasize, "Clearly, new targets and drugs need to be identified, if response and survival are to be improved."

Two features of renal-cell carcinoma suggest that the future of treatment for renal cancer lies in immunologic or targeted therapeutic strategies. First, renal-cell carcinoma occasionally responds . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.